BioStock: Biologics are a success factor according to Lipum

Lipum develops a new biological drug for chronic inflammatory diseases. According to one study, the probability for approval of biological drugs is almost twice as high as that of small molecules (new molecular entities, NME). This bodes well for Lipum’s drug candidate SOL-116, which is an antibody. In addition, it has the potential to achieve orphan drug status, which would further increase the chances as it provides many benefits during the development process.

Read the full article at

This is a press release from BioStock - Connecting Innovation & Capital.

About Us

Lipum is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores several other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant.


Documents & Links

Quick facts

BioStock: Biologics are a success factor according to Lipum
Tweet this